JOHNSON & JOHNSON · 2026-10-30 · Importance 26 · Surprise 24
Johnson & Johnson’s MedTech performance fell below internal expectations in the third quarter. The reported weakness was driven mainly by challenges in international markets, particularly in Cardiovascular and Surgery, and continued softness in the Abiomed business. The report identifies international Cardiovascular and Surgery markets and Abiomed as the areas weighing on performance.
Key facts
Johnson & Johnson's MedTech performance fell below internal expectations in the third quarter, mainly due to challenges in international markets, particularly in Cardiovascular and Surgery, and continued softness in Abiomed. source
Johnson & Johnson's MedTech business was underperforming. source